Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Down 39.2% in February

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the target of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 567,600 shares, a decrease of 39.2% from the February 13th total of 934,300 shares. Based on an average trading volume of 955,300 shares, the short-interest ratio is presently 0.6 days. Approximately 0.8% of the shares of the stock are short sold.

Tiziana Life Sciences Stock Performance

NASDAQ TLSA traded up $0.09 during mid-day trading on Friday, hitting $1.57. The stock had a trading volume of 375,854 shares, compared to its average volume of 433,491. The company has a 50 day simple moving average of $0.90 and a 200 day simple moving average of $0.92. Tiziana Life Sciences has a 52-week low of $0.41 and a 52-week high of $1.91.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Sanctuary Advisors LLC acquired a new stake in Tiziana Life Sciences in the 3rd quarter valued at about $864,000. Zhang Financial LLC lifted its holdings in shares of Tiziana Life Sciences by 34.3% in the fourth quarter. Zhang Financial LLC now owns 93,187 shares of the company’s stock valued at $65,000 after purchasing an additional 23,800 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Tiziana Life Sciences by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock valued at $171,000 after purchasing an additional 27,041 shares during the last quarter. Finally, Bison Wealth LLC purchased a new position in shares of Tiziana Life Sciences during the 4th quarter worth approximately $30,000.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.